Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lavie

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Leukemia Research|September 15, 2015
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practiceMartin H Ellis, Noa Lavi, Elena Mishchenko, et al.
The Lancet. Haematology|December 25, 2017
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trialClaire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, et al.
European Journal of Haematology|April 25, 2023
Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortalityShlomzion Aumann, Uria Tsubary, Boaz Nachmias, et al.
Leukemia & Lymphoma|May 2, 2022
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphomaEyal Lebel, Neta Goldschmidt, Tali Siegal, et al.
Blood Neoplasia|June 2, 2025
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal responseNaveen Pemmaraju, Tim C P Somervaille, Francesca Palandri, et al.
Blood Advances|April 12, 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrdan Verstovsek, Ruben Mesa, Vikas Gupta, et al.
British Journal of Haematology|June 8, 2017
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patientsEldad J Dann, Osnat Bairey, Rachel Bar-Shalom, et al.
Blood Advances|March 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosisJohn O Mascarenhas, Laura Maria Fogliatto, Steven D Green, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Leukemia Research|September 15, 2015
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practiceMartin H Ellis, Noa Lavi, Elena Mishchenko, et al.
The Lancet. Haematology|December 25, 2017
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trialClaire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, et al.
European Journal of Haematology|April 25, 2023
Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortalityShlomzion Aumann, Uria Tsubary, Boaz Nachmias, et al.
Leukemia & Lymphoma|May 2, 2022
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphomaEyal Lebel, Neta Goldschmidt, Tali Siegal, et al.
Blood Neoplasia|June 2, 2025
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal responseNaveen Pemmaraju, Tim C P Somervaille, Francesca Palandri, et al.
Blood Advances|April 12, 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrdan Verstovsek, Ruben Mesa, Vikas Gupta, et al.
British Journal of Haematology|June 8, 2017
Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patientsEldad J Dann, Osnat Bairey, Rachel Bar-Shalom, et al.
Blood Advances|March 17, 2026
Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy in patients with myelofibrosisJohn O Mascarenhas, Laura Maria Fogliatto, Steven D Green, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Pageof 3